文献速递前列腺癌

真实世界队列中前列腺癌主动监测:符合与不符合PRIAS标准患者结局比较

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

在六家大型教学医院2008至2015年诊断并接受主动监测的1000例前列腺癌患者中,49%不符合PRIAS纳入标准。不符合者肿瘤进展而停止主动监测的风险显著更高(HR 1.74,95%CI 1.44-2.11),延迟根治性前列腺切除术后切缘阳性(OR 2.15,95%CI 1.11-4.17)和不利病理发现(OR 3.20,95%CI 1.61-6.35)风险也更高。PSA密度≥0.2 ng/ml/ml是最重要的个体预测因素。

要点

  • 真实世界主动监测队列中49%患者不符合PRIAS纳入标准。
  • 不符合PRIAS者肿瘤进展停止主动监测风险更高(HR 1.74)。
  • PSA密度≥0.2 ng/ml/ml与进展和转移风险升高相关。

核心结论

  • 本队列中约半数患者不符合PRIAS研究纳入标准,这些患者疾病进展和延迟前列腺切除术后不利结局的风险高2至3倍。
  • PSA密度是不利结局的重要个体预测因素,选择主动监测患者时应加以考虑。

研究设计与样本

  • 研究纳入2008至2015年在六家大型教学医院诊断、临床分期≥T1c并接受主动监测的前列腺癌患者,共1000例。
  • 主动监测包括每3至6个月检测前列腺特异性抗原(PSA),诊断后1年进行确认性活检,此后每3年一次。
  • 采用PRIAS研究纳入标准(cT1c-T2、Gleason总和评分≤6、阳性活检针数≤2、PSA≤10 ng/ml、PSA密度<0.2 ng/ml/ml)将患者分为符合PRIAS组与不符合PRIAS组进行比较。
  • 采用单变量和多变量Cox回归分析计算延迟手术后的不利结局、生化复发和转移风险,采用生存分析确定肿瘤进展时间。

主要发现

  • 纳入并接受主动监测的1000例患者中,49%具有高于PRIAS纳入标准的高危疾病特征。
  • 不符合PRIAS患者因肿瘤进展停止主动监测显著早于符合PRIAS患者(HR 1.74,95%CI 1.44-2.11)。
  • 延迟根治性前列腺切除术后,不符合PRIAS患者切缘阳性风险更高(OR 2.15,95%CI 1.11-4.17),不利病理发现风险也更高(OR 3.20,95%CI 1.61-6.35)。
  • PSA密度≥0.2 ng/ml/ml是最重要的个体预测因素,除与肿瘤进展和不利手术结局风险更高相关外,还与延迟根治性前列腺切除术后生化进展风险显著更高相关(OR 3.26,95%CI 1.23-8.64)。
  • 在总体人群中,PSA密度≥0.2 ng/ml/ml也与转移风险更高相关(HR 2.71,95%CI 1.23-5.96)。

关键数值与推荐

  • PRIAS纳入标准:cT1c-T2、Gleason总和评分≤6、阳性活检针数≤2、PSA≤10 ng/ml、PSA密度<0.2 ng/ml/ml。
  • 不符合PRIAS患者因肿瘤进展停止主动监测的HR为1.74(95%CI 1.44-2.11)。
  • 不符合PRIAS患者延迟根治性前列腺切除术后切缘阳性的OR为2.15(95%CI 1.11-4.17),不利病理发现的OR为3.20(95%CI 1.61-6.35)。
  • PSA密度≥0.2 ng/ml/ml与延迟根治性前列腺切除术后生化进展相关(OR 3.26,95%CI 1.23-8.64),在总体人群中与转移风险相关(HR 2.71,95%CI 1.23-5.96)。

临床怎么用

  • 作者认为PSA密度是选择主动监测患者时应考虑的重要个体预测因素。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In daily practice, a wider range of patients with prostate cancer (PCa) are selected for active surveillance (AS) compared to those in AS trials, including higher-risk patients. However, less is known about the outcomes for off-protocol selected PCa patients who opt for AS. OBJECTIVE: To compare AS outcomes for higher-risk patients and very low-risk patients in a large cohort of patients diagnosed with PCa. DESIGN, SETTING, AND PARTICIPANTS: Patients diagnosed with PCa between 2008 and 2015 with clinical stage ≥T1c and managed with AS at six large teaching hospitals. INTERVENTION: AS included regular prostate-specific antigen (PSA) testing (every 3-6 mo) and a confirmatory biopsy 1 yr after diagnosis and every 3 yr thereafter. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: Using the inclusion criteria of the PRIAS study, outcomes for PRIAS-eligible patients (ie, cT1c-T2, Gleason sum score ≤6, ≤2 positive biopsy cores, PSA ≤10 ng/ml, and PSA density <0.2 ng/ml/ml) were compared to outcomes for PRIAS-ineligible patients. Unfavourable outcomes following deferred surgery, biochemical recurrence, and risk of metastasis were calculated using univariate and multivariate Cox regression analyses. Time to tumour progression was established using survival analysis. RESULTS AND LIMITATIONS: Of the 1000 patients included and managed with AS, almost half of the patients (49%) had higher-risk disease characteristics than the PRIAS inclusion criteria. PRIAS-ineligible patients discontinued AS because of tumour progression significantly earlier than PRIAS-eligible patients (hazard ratio [HR] 1.74, 95% confidence interval [CI] 1.44-2.11); they also had a higher risk of positive surgical margins (odds ratio [OR] 2.15, 95% CI 1.11-4.17) and unfavourable pathological findings (OR 3.20, 95% CI 1.61-6.35) following deferred radical prostatectomy. PSA density ≥0.2 ng/ml/ml was the most important individual predictor and, in addition to a higher risk of tumour progression and unfavourable surgical outcomes, was also associated with a significantly higher risk of biochemical progression following deferred radical prostatectomy (OR 3.26, 95% CI 1.23-8.64). In the overall population, PSA density ≥0.2 ng/ml/ml was also associated with a higher risk of metastasis (HR 2.71, 95% CI 1.23-5.96). CONCLUSIONS: In this cohort, approximately half of the patients did not meet the inclusion criteria of the PRIAS study. These patients had a two- to threefold higher risk of disease progression and unfavourable outcomes following deferred prostatectomy. PSA density is an important individual predictor of unfavourable outcomes and should be taken into account when selecting patients for AS. PATIENT SUMMARY: A large proportion of patients with prostate cancer on active surveillance are not in the lowest risk group. These patients have a higher risk of experiencing tumour progression to a stage requiring curative intervention. They also have worse disease prognosis compared to patients on active surveillance in the lowest risk group.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Soeterik TFW, van Melick HHE, Dijksman LM, et al. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients. Eur Urol Oncol. 2018. PMID: 31102626. doi:10.1016/j.euo.2018.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。